{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:29:13Z","timestamp":1773084553168,"version":"3.50.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bcp.2021.114431","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T11:24:12Z","timestamp":1611833052000},"page":"114431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking"],"prefix":"10.1016","volume":"185","author":[{"given":"Claire","family":"Lugnier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayder M.","family":"Al-Kuraishy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.bcp.2021.114431_b0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.bcp.2021.114431_b0010","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2021.114431_b0015","doi-asserted-by":"crossref","unstructured":"F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, et al., Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-1062, 2020.","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"10.1016\/j.bcp.2021.114431_b0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/ITT.S264138","article-title":"Assessing immune response to SARS-CoV-2 infection","volume":"9","author":"Shurin","year":"2020","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.bcp.2021.114431_b0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.bcp.2021.114431_b0030","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1513\/AnnalsATS.201706-464MG","article-title":"Nicotine downregulates the compensatory angiotensin-converting enzyme 2\/angiotensin type 2 receptor of the renin\u2013angiotensin system","volume":"15","author":"Yue","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0035","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE Inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Keravis","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0040","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/odi.12275","article-title":"Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets","volume":"21","author":"Ahmad","year":"2015","journal-title":"Oral Dis."},{"issue":"10","key":"10.1016\/j.bcp.2021.114431_b0045","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2021.114431_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107475","article-title":"Cyclic nucleotide phosphodiesterases: new targets in the metabolic syndrome?","volume":"208","author":"Lugnier","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0055","doi-asserted-by":"crossref","first-page":"R895","DOI":"10.1152\/ajpregu.00099.2018","article-title":"Nicotine and the renin-angiotensin system","volume":"315","author":"Oakes","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"5137","key":"10.1016\/j.bcp.2021.114431_b0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/218144a0","article-title":"Fate of angiotensin I in the circulation","volume":"218","author":"Ng","year":"1968","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0065","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1513\/AnnalsATS.201604-317OC","article-title":"Angiotensin-converting inhibitors and angiotensin II receptor blockers and longitudinal change in percent emphysema on computed tomography. The multi-ethnic study of atherosclerosis lung study","volume":"14","author":"Parikh","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"3","key":"10.1016\/j.bcp.2021.114431_b0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/SHK.0000000000000633","article-title":"Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease","volume":"46","author":"Jia","year":"2016","journal-title":"Shock"},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0075","doi-asserted-by":"crossref","first-page":"L662","DOI":"10.1152\/ajplung.00389.2017","article-title":"Comparison of the effects of e-cigarette vapor with cigarette smoke on lung function and inflammation in mice","volume":"315","author":"Glynos","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12931-020-01396-y","article-title":"E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR \u03b17 receptor: role of nAChR \u03b17 in SARS-CoV-2 Covid-19 ACE2 receptor regulation","volume":"21","author":"Wang","year":"2020","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5802\/crbiol.8","article-title":"A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications","volume":"343","author":"Changeux","year":"2020","journal-title":"C R Biol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114431_b0090","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ntr\/ntaa077","article-title":"Beyond smoking cessation: investigating medicinal nicotine to prevent and treat COVID-19","volume":"22","author":"Tindle","year":"2020","journal-title":"Nicotine Tob. Res."},{"issue":"8","key":"10.1016\/j.bcp.2021.114431_b0095","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1074\/jbc.R200029200","article-title":"Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling","volume":"278","author":"Conti","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0100","doi-asserted-by":"crossref","first-page":"L743","DOI":"10.1152\/ajplung.00373.2017","article-title":"Effects of cigarette smoke on pulmonary endothelial cells","volume":"314","author":"Lu","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/cp.cp_3_19","article-title":"Correlation between plasma-soluble angiotensin-converting enzyme 2, anti-angiotensin-converting enzyme 2, and angiotensin-(1\u20137) in patients with chronic heart failure","volume":"4","author":"Gu","year":"2019","journal-title":"Cardiol. Plus"},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI46215","article-title":"Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice","volume":"122","author":"Podowski","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2021.114431_b0115","doi-asserted-by":"crossref","unstructured":"I. Berlin, D. Thomas, A.L. Le Faou, J. Cornuz, COVID-19 and smoking [published online ahead of print, 2020 Apr 3]. Nicotine Tob Res. ntaa059. doi: 10.1093\/ntr\/ntaa059.","DOI":"10.1093\/ntr\/ntaa059"},{"issue":"18","key":"10.1016\/j.bcp.2021.114431_b0120","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bcp.2021.114431_b0125","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed asymptomatic carrier transmission of COVID-19","volume":"323","author":"Bai","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2021.114431_b0130","article-title":"Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population?","author":"Ods","year":"2020","journal-title":"FEBS J."},{"issue":"9","key":"10.1016\/j.bcp.2021.114431_b0135","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/s41401-020-0430-6","article-title":"Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication","volume":"41","author":"Pang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2021.114431_b0140","doi-asserted-by":"crossref","unstructured":"Pena Silva RA. Cardiovascular oxidative stress: recent findings on ACE2 and MAO. 2012. doi: 10.17077\/etd.109quuf9.","DOI":"10.17077\/etd.109quuf9"},{"key":"10.1016\/j.bcp.2021.114431_b0145","doi-asserted-by":"crossref","first-page":"454","DOI":"10.7150\/ijbs.13379","article-title":"Alternative roles of STAT3 and MAPK signaling pathways in the MMPs activation and progression of lung injury induced by cigarette smoke exposure in ACE2 knockout mice","volume":"12","author":"Hung","year":"2016","journal-title":"Int. J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2021.114431_b0150","doi-asserted-by":"crossref","first-page":"2001116","DOI":"10.1183\/13993003.01116-2020","article-title":"COVID-19 and smoking: is nicotine the hidden link?","volume":"55","author":"Russo","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bcp.2021.114431_b0155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.18332\/tid\/119324","article-title":"COVID-19 and smoking: a systematic review of the evidence","volume":"18","author":"Vardavas","year":"2020","journal-title":"Tob. Induc. Dis."},{"key":"10.1016\/j.bcp.2021.114431_b0160","doi-asserted-by":"crossref","unstructured":"Q. Cui, C. Huang, X. Ji, W. Zhang, F. Zhang, L. Wang, Possible inhibitors of ACE2, the receptor of 2019-nCoV. 2020 Preprints 2020020047 (doi: 10.20944\/ preprints202002.0047.v1).","DOI":"10.20944\/preprints202002.0047.v1"},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233147","article-title":"Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis","volume":"15","author":"Alqahtani","year":"2020","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.bcp.2021.114431_b0170","article-title":"Smoking doubles the mortality risk in COVID-19: a meta-analysis of recent reports and potential mechanisms","volume":"12","author":"Salah","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.bcp.2021.114431_b0175","doi-asserted-by":"crossref","unstructured":"D. Simons, L. Shahab, J. Brown, O. Perski, The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction. 2020 Oct 2:10.1111\/add.15276. doi: 10.1111\/add.15276.","DOI":"10.32388\/UJR2AW.8"},{"issue":"10","key":"10.1016\/j.bcp.2021.114431_b0180","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/0006-2952(86)90333-3","article-title":"Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta","volume":"35","author":"Lugnier","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114431_b0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00926755","article-title":"Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium","volume":"140","author":"Rousseau","year":"1994","journal-title":"Mol. Cell. Biochem."},{"issue":"12","key":"10.1016\/j.bcp.2021.114431_b0190","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1139\/y95-243","article-title":"Specific cyclic nucleotide phosphodiesterase inhibitors differently modulate contractile kinetics in airway smooth muscle","volume":"73","author":"Rousseau","year":"1995","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114431_b0195","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0006-2952(02)00919-X","article-title":"Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery","volume":"63","author":"Pauvert","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114431_b0200","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1160\/TH03-12-0768","article-title":"Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4","volume":"92","author":"Favot","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcp.2021.114431_b0205","unstructured":"T. Keravis, P.A. Silva, L. Favot, C. Lugnier, Role of PDEs in vascular health and disease : Endothelial PDEs and angiogenesis. In: JA Beavo, SH Francis, & MD Houslay (Eds.). Cyclic Nucleotide Phosphodiesterases in Health and Disease.(pp.419-439). Boca Raton: CRC Press."},{"key":"10.1016\/j.bcp.2021.114431_b0210","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114431_b0215","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1021\/jm960827x","article-title":"9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors","volume":"40","author":"Bourguignon","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2021.114431_b0220","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0022-3565(24)35335-2","article-title":"Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine","volume":"292","author":"Boichot","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028899","article-title":"Disease progression in MRL\/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor","volume":"7","author":"Keravis","year":"2012","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.bcp.2021.114431_b0230","doi-asserted-by":"crossref","first-page":"L441","DOI":"10.1152\/ajplung.00407.2010","article-title":"NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues","volume":"301","author":"Yougbare","year":"2011","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.bcp.2021.114431_b0235","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3389\/fphar.2020.01266","article-title":"NCS 613, a potent PDE4 inhibitor, displays anti-inflammatory and anti-proliferative properties on A549 lung epithelial cells and human lung adenocarcinoma explants","volume":"11","author":"Yougbare","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114431_b0240","doi-asserted-by":"crossref","unstructured":"I. Yougbare, T. Keravis, C. Lugnier, NCS 613, a PDE4 inhibitor, by increasing cAMP level suppresses systemic inflammation and immune complexes deposition in kidney of MRL\/lpr lupus- prone mice. Biochim Biophys Acta Mol Basis Dis. 2020;166019. doi: 10.1016\/j.bbadis.2020.166019. Online ahead of print. PMID: 33227426.","DOI":"10.1016\/j.bbadis.2020.166019"},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0245","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1139\/cjpp-2012-0233","article-title":"NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-\u03baB signalling pathways while reducing proinflammatory cytokine production","volume":"91","author":"Yougbar\u00e9","year":"2013","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0250","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0255","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0960-894X(98)00058-4","article-title":"Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds","volume":"8","author":"Segarra","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bcp.2021.114431_b0260","first-page":"5493","article-title":"Bidirectional modulation of exocytosis by angiotensin II involves multiple G-protein-regulated transduction pathways in chromaffin cells","volume":"278","author":"Teschemacher","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2021.114431_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014227","article-title":"Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II","volume":"5","author":"Mokni","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2021.114431_b0270","doi-asserted-by":"crossref","unstructured":"Y. Liang, J. Xie, D. Che, C. Zhang, Y. Lin, L. Feng, et al., MiR-124-3p helps to protect against acute respiratory distress syndrome by targeting p65 Biosci Rep. 2020;40(5):BSR20192132.","DOI":"10.1042\/BSR20192132"},{"issue":"2","key":"10.1016\/j.bcp.2021.114431_b0275","first-page":"1003","article-title":"MicroRNA-124-3p attenuates severe community\u2013acquired pneumonia progression in macrophages by targeting tumor necrosis factor receptor\u2013associated factor 6","volume":"43","author":"Gao","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bcp.2021.114431_b0280","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1096\/fj.201700673r","article-title":"Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons","volume":"32","author":"Huang","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2021.114431_b0285","first-page":"1003","article-title":"MicroRNA-124-3p attenuates severe community-acquired pneumonia progression in macrophages by targeting tumor necrosis factor receptor-associated factor 6","volume":"43","author":"Gao","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bcp.2021.114431_b0290","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/jcm9030841","article-title":"Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19)","volume":"9","author":"Brake","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.bcp.2021.114431_b0295","doi-asserted-by":"crossref","first-page":"L332","DOI":"10.1152\/ajplung.00384.2003","article-title":"Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers","volume":"287","author":"Barber","year":"2004","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"14","key":"10.1016\/j.bcp.2021.114431_b0300","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1111\/bph.14347","article-title":"Cigarette smoke up-regulates PDE3 and PDE4 to decrease cAMP in airway cells","volume":"175","author":"Zuo","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114431_b0305","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/00002030-199510000-00004","article-title":"Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication","volume":"9","author":"Angel","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2021.114431_b0310","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1128\/JVI.72.6.4712-4720.1998","article-title":"Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-\u03baB and NFAT","volume":"72","author":"Navarro","year":"1998","journal-title":"J. Virol."},{"issue":"26","key":"10.1016\/j.bcp.2021.114431_b0315","doi-asserted-by":"crossref","first-page":"14620","DOI":"10.1073\/pnas.011512398","article-title":"Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication","volume":"97","author":"Secchiero","year":"2000","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.bcp.2021.114431_b0320","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.4049\/jimmunol.165.4.1755","article-title":"Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4","volume":"165","author":"Sun","year":"2000","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114431_b0325","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/infdis\/jix547","article-title":"Regulatory T Cells Contribute to HIV-1 Reservoir persistence in CD4+ T cells through cyclic adenosine monophosphate\u2013dependent mechanisms in humanized mice in vivo","volume":"216","author":"Li","year":"2017","journal-title":"J Inf Dis."},{"key":"10.1016\/j.bcp.2021.114431_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.129868","article-title":"Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico \/ in vitro assessment","volume":"1230","author":"Chemboli","year":"2021","journal-title":"J. Mol. Struct."},{"issue":"8","key":"10.1016\/j.bcp.2021.114431_b0335","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS Coronavirus-Induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2021.114431_b0340","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.bcp.2021.114431_b0345","first-page":"335","article-title":"Rationale for evaluating PDE4 inhibition for mitigating against severe inflammation in COVID-19 pneumonia and beyond","volume":"22","author":"Bridgewood","year":"2020","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.bcp.2021.114431_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154282","article-title":"Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19","volume":"109","author":"Dalamaga","year":"2020","journal-title":"Metab. Clin. Exper."},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0355","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41598-018-37813-y","article-title":"Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing","volume":"9","author":"Vautrin","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2021.114431_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.bcp.2021.114431_b0365","doi-asserted-by":"crossref","unstructured":"M. Kono, K. Tatsumi, A.M. Imai, K. Saito, T. Kuriyama, H. Shirasawa, Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antivir. Res. 20008; 77. doi: 10.1016\/j.antiviral.2007.10.011.","DOI":"10.1016\/j.antiviral.2007.10.011"},{"key":"10.1016\/j.bcp.2021.114431_b0370","unstructured":"https:\/\/www.ox.ac.uk\/news\/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe."},{"key":"10.1016\/j.bcp.2021.114431_b0375","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12931-016-0325-8","article-title":"Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells","volume":"17","author":"Grundy","year":"2016","journal-title":"Respir. Res."},{"key":"10.1016\/j.bcp.2021.114431_b0380","article-title":"Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19","volume":"9","author":"Maldonado","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"10","key":"10.1016\/j.bcp.2021.114431_b0385","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00018-016-2446-0","article-title":"Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions","volume":"74","author":"Tetsi","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"issue":"15","key":"10.1016\/j.bcp.2021.114431_b0390","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms21155338","article-title":"Phosphodiesterase inhibitors: could they be beneficial for the treatment of COVID-19?","volume":"21","author":"Giorgi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0395","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0006-2952(90)90650-A","article-title":"Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells","volume":"39","author":"Lugnier","year":"1990","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114431_b0400","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1160\/TH03-02-0084","article-title":"VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors","volume":"90","author":"Favot","year":"2003","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.bcp.2021.114431_b0405","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3390\/cells9071652","article-title":"COVID-19, renin-angiotensin system and endothelial dysfunction","volume":"9","author":"Amraei","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bcp.2021.114431_b0410","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1113\/jphysiol.2012.232116","article-title":"Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation","volume":"590","author":"Schick","year":"2012","journal-title":"J. Physiol."},{"issue":"Suppl 10","key":"10.1016\/j.bcp.2021.114431_b0415","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1289\/ehp.94102s1079","article-title":"Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma","volume":"102 Suppl 10","author":"Torphy","year":"1994","journal-title":"Environ. Health Perspect."},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1465-9921-7-9","article-title":"Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells","volume":"7","author":"Growcott","year":"2006","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.bcp.2021.114431_b0425","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bjp.0701376","article-title":"Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity","volume":"122","author":"Rose","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114431_b0430","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/bjp.2008.56","article-title":"Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells","volume":"154","author":"Campos-Toimil","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114431_b0435","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:22:42Z","timestamp":1757769762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221000277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":87,"alternative-id":["S0006295221000277"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114431","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114431"}}